Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of aH5N1 Vaccine in Adults and Elderly
NCT02107807Phase 3Completed
- Sponsor
- CSL Seqirus
- Start
- Apr 2014
- Primary completion
- May 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 3, randomised, single-blind trial of MF59-eH5N1 in Avian Influenza (AI) (4 arms), sponsored by CSL Seqirus. Primary endpoints: Percentage of subjects achieving seroconversion determined by Hemagglutination Inhibition at Day 43, Geometric Mean Ratios determined by Hemagglutination Inhibition at Day 43 and 2 more. Started Apr 2014; status: completed.
02
Drugs
MF59-eH5N1
03
Conditions
Avian Influenza (AI)
Beyond the preview
Go deeper on NCT02107807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02107807.